Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2025 17:00 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was...
May 14, 2025 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Updates on INZ-701
April 10, 2025 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
March 31, 2025 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 10, 2025 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program
February 24, 2025 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Inozyme Pharma CEO Doug Treco will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025
February 21, 2025 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
January 10, 2025 08:00 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
November 27, 2024 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Inozyme's COO Matt Winton will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference
November 11, 2024 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...